RxDoctor Payments Data

Benjamin Bosen, DO

Family Medicine · Garden City, UTNPI 1134655756

Payments from drug & device makers

$911in general payments, 2019–2025

Across 58 payments — averaging $15.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$249
  • Amgen$178
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$102
  • Pfizer$63
  • Novo Nordisk$53
  • Myriad Women's Health, Inc.$37
  • plus $228 from 11 others

What the payments were for

  • Food & beverage$911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$911 in reported general payments places this provider in the 60th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$6,114
Medicare patients
33
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$144,884
FarxigaDapagliflozin Propanediol141$80,451
JardianceEmpagliflozin122$73,499
Trijardy XrEmpaglifloz/Linaglip/Metformin120$70,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$63,075
OzempicSemaglutide63$59,773
XareltoRivaroxaban91$48,576
MounjaroTirzepatide38$39,960
RybelsusSemaglutide32$30,833
GemtesaVibegron55$26,311
Synjardy XrEmpagliflozin/Metformin Hcl42$21,511
QuliptaAtogepant19$20,363
JanuviaSitagliptin Phosphate24$15,480
TradjentaLinagliptin26$13,330
MyrbetriqMirabegron27$12,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr, Tradjenta, Glyxambi$16$190,401330 claims
PfizerEliquis, Premarin$63$152,960283 claims
Novo NordiskOzempic, Rybelsus, Novolog$53$92,836117 claims
AstraZenecaFarxiga$23$80,451141 claims
Johnson & JohnsonXarelto$29$48,57691 claims
AbbVieQulipta, Linzess, Restasis$249$29,51946 claims
Sumitomo Pharma America, Inc.Gemtesa$7$26,31155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 928 family medicine providers in Utah.

Other family medicine in Garden City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →